BioCentury | Dec 3, 2012
Clinical News

VIA-3196: Phase I data

...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Dec 3, 2012
Clinical News

VIA-3196: Phase I data

...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Mar 12, 2012
Clinical News

VIA-3196: Phase I started

...elevated LDL-C. Madrigal gained 3196 last September, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Jun 20, 2011
Clinical News

VIA-3196: Phase I started

...worldwide rights to develop and commercialize the compound from Roche (see BioCentury, Jan. 5, 2009). Via Pharmaceuticals Inc....
BioCentury | Mar 17, 2011
Distillery Therapeutics

Indication: Various

...Co. Inc.'s 5-LO inhibitor, MK-0633, is in Phase II for chronic obstructive pulmonary disease (COPD). Via Pharmaceuticals Inc.'s...
BioCentury | Oct 28, 2010
Cover Story

DGAT out of the bag

...lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc....
...Jolla, Calif. University of California, San Francisco , Calif. University Paris Descartes , Paris, France Via Pharmaceuticals Inc....
BioCentury | Oct 21, 2010
Distillery Therapeutics

Indication: Infectious disease

...compared with vehicle. Next steps include testing the DGAT1 inhibitor in humanized mice. Roche and Via Pharmaceuticals Inc....
BioCentury | May 27, 2010
Targets & Mechanisms

The case against triglycerides

...of R&D at Via Pharmaceuticals Inc. "It's a very complex area involving triglyceride biosynthesis, absorption and clearance." Via Pharmaceuticals...
...of Cambridge , Cambridge, U.K. The University of Sydney , Sydney, New South Wales, Australia Via Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Company News

Via Pharmaceuticals cardiovascular, metabolic, endocrine news

...$1.3 million in a note offering. The notes bear 15% interest and mature in December. Via Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

...function, missed the co-primary endpoints in patients with mild to moderate Alzheimer's disease (AD) 3/31/10 Via Pharmaceuticals Inc....
Items per page:
1 - 10 of 42
BioCentury | Dec 3, 2012
Clinical News

VIA-3196: Phase I data

...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Dec 3, 2012
Clinical News

VIA-3196: Phase I data

...Los Angeles. Madrigal gained MGL-3196 in 2011, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Mar 12, 2012
Clinical News

VIA-3196: Phase I started

...elevated LDL-C. Madrigal gained 3196 last September, when it acquired all of the assets of Via Pharmaceuticals Inc....
BioCentury | Jun 20, 2011
Clinical News

VIA-3196: Phase I started

...worldwide rights to develop and commercialize the compound from Roche (see BioCentury, Jan. 5, 2009). Via Pharmaceuticals Inc....
BioCentury | Mar 17, 2011
Distillery Therapeutics

Indication: Various

...Co. Inc.'s 5-LO inhibitor, MK-0633, is in Phase II for chronic obstructive pulmonary disease (COPD). Via Pharmaceuticals Inc.'s...
BioCentury | Oct 28, 2010
Cover Story

DGAT out of the bag

...lipid droplet biogenesis, is a host factor for HCV infection. 1 The results have prompted Via Pharmaceuticals Inc....
...Jolla, Calif. University of California, San Francisco , Calif. University Paris Descartes , Paris, France Via Pharmaceuticals Inc....
BioCentury | Oct 21, 2010
Distillery Therapeutics

Indication: Infectious disease

...compared with vehicle. Next steps include testing the DGAT1 inhibitor in humanized mice. Roche and Via Pharmaceuticals Inc....
BioCentury | May 27, 2010
Targets & Mechanisms

The case against triglycerides

...of R&D at Via Pharmaceuticals Inc. "It's a very complex area involving triglyceride biosynthesis, absorption and clearance." Via Pharmaceuticals...
...of Cambridge , Cambridge, U.K. The University of Sydney , Sydney, New South Wales, Australia Via Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Company News

Via Pharmaceuticals cardiovascular, metabolic, endocrine news

...$1.3 million in a note offering. The notes bear 15% interest and mature in December. Via Pharmaceuticals Inc....
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

...function, missed the co-primary endpoints in patients with mild to moderate Alzheimer's disease (AD) 3/31/10 Via Pharmaceuticals Inc....
Items per page:
1 - 10 of 42